Teva Pharmaceutical Industries Ltd (NYSE:TEVA) EVP Sven Dethlefs sold 647 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.67, for a total value of $10,138.49. Following the completion of the sale, the executive vice president now owns 9,249 shares of the company’s stock, valued at $144,931.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Sven Dethlefs also recently made the following trade(s):

Get Teva Pharmaceutical Industries alerts:

On Monday, March 4th, Sven Dethlefs sold 606 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $16.88, for a total value of $10,229.28.

Teva Pharmaceutical Industries stock traded up $0.04 during trading hours on Friday, reaching $16.51. The stock had a trading volume of 6,617,760 shares, compared to its average volume of 10,353,678. The company has a market capitalization of $16.78 billion, a PE ratio of 5.90, a P/E/G ratio of 2.96 and a beta of 1.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.63 and a current ratio of 0.96. Teva Pharmaceutical Industries Ltd has a 52 week low of $14.59 and a 52 week high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, February 13th. The company reported $0.53 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.53. The business had revenue of $4.56 billion during the quarter, compared to the consensus estimate of $4.52 billion. Teva Pharmaceutical Industries had a negative net margin of 11.40% and a positive return on equity of 18.57%. The firm’s revenue was down 15.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.93 earnings per share. On average, equities analysts predict that Teva Pharmaceutical Industries Ltd will post 2.33 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. Rehmann Capital Advisory Group increased its holdings in shares of Teva Pharmaceutical Industries by 8.8% during the third quarter. Rehmann Capital Advisory Group now owns 9,814 shares of the company’s stock valued at $211,000 after acquiring an additional 795 shares in the last quarter. Hancock Whitney Corp increased its holdings in shares of Teva Pharmaceutical Industries by 7.8% during the fourth quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock valued at $186,000 after acquiring an additional 868 shares in the last quarter. Financial Counselors Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 0.7% during the fourth quarter. Financial Counselors Inc. now owns 124,805 shares of the company’s stock valued at $1,924,000 after acquiring an additional 872 shares in the last quarter. Hartford Investment Management Co. increased its holdings in shares of Teva Pharmaceutical Industries by 3.1% during the fourth quarter. Hartford Investment Management Co. now owns 29,581 shares of the company’s stock valued at $456,000 after acquiring an additional 902 shares in the last quarter. Finally, Nwam LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3.1% during the fourth quarter. Nwam LLC now owns 30,083 shares of the company’s stock valued at $464,000 after acquiring an additional 915 shares in the last quarter. Institutional investors and hedge funds own 66.42% of the company’s stock.

Several analysts recently weighed in on the company. UBS Group assumed coverage on Teva Pharmaceutical Industries in a report on Thursday, March 7th. They issued a “buy” rating and a $22.00 price objective for the company. Morgan Stanley downgraded Teva Pharmaceutical Industries from an “overweight” rating to an “equal weight” rating and set a $17.00 price objective for the company. in a report on Wednesday, March 6th. Mizuho downgraded Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $25.00 to $18.00 in a report on Wednesday, February 20th. Credit Suisse Group decreased their price objective on Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating for the company in a report on Thursday, February 14th. Finally, Raymond James upgraded Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $22.00 price objective for the company in a report on Thursday, February 14th. Three investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $21.21.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Ltd (TEVA) EVP Sven Dethlefs Sells 647 Shares” was originally published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/4224548/teva-pharmaceutical-industries-ltd-teva-evp-sven-dethlefs-sells-647-shares.html.